January 9, 2018 / 2:20 PM / Updated 6 minutes ago BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab Reuters Staff 
Jan 9 (Reuters) - Beigene Ltd: 
* BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB 
* BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE 
* BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA Source text for Eikon: Further company coverage: